Synthesized boron compounds: Neurotoxic and oxidative effects in an in vitro model of Alzheimer's disease
| dc.contributor.author | Bayil, Sibel | |
| dc.contributor.author | Tozlu, Ozlem Ozdemir | |
| dc.contributor.author | Karagul, Bora | |
| dc.date.accessioned | 2026-07-01T11:39:42Z | |
| dc.date.available | 2026-07-01T11:39:42Z | |
| dc.date.issued | 2025 | |
| dc.department | Düzce Üniversitesi | |
| dc.description.abstract | Objective Alzheimer's disease (AD) is characterized by amyloid-beta (A beta 1-42) aggregation, oxidative stress, and neuronal loss, necessitating novel therapeutic agents to mitigate these pathological hallmarks. Method This study investigates the neuroprotective and antioxidant properties of newly synthesized borenium (compounds 1-4) and borinium (compounds 5-8) derivatives in an in vitro AD model using differentiated SH-SY5Y neuroblastoma cells exposed to A beta 1-42. Furthermore, automated Total Antioxidant Capacity assays were conducted using commercially available kits on culture media collected from cell cultures following 24 h of incubation. 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide and lactate dehydrogenase tests were done to determine the cytotoxicity of boron compounds after application to the exposed cell lines of A beta 1-42. Results It was determined that the boron compounds applied to the cell lines at different concentrations did not show any neurotoxic effect at a concentration of 50 mu M in 24 h of incubation. All boron compounds were determined to have antioxidant properties. It was found that the borinium compounds are much more neuroprotective than the borenium. Conclusion These findings highlight the therapeutic potential of borenium and borinium compounds as neuroprotective and antioxidant agents for AD, warranting further mechanistic and in vivo studies. | |
| dc.identifier.doi | 10.1177/00368504251384830 | |
| dc.identifier.issn | 0036-8504 | |
| dc.identifier.issn | 2047-7163 | |
| dc.identifier.issue | 4 | |
| dc.identifier.orcid | 0000-0003-0254-6915 | |
| dc.identifier.pmid | 41091796 | |
| dc.identifier.scopus | 2-s2.0-105018892842 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | https://doi.org/10.1177/00368504251384830 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12684/23433 | |
| dc.identifier.volume | 108 | |
| dc.identifier.wos | WOS:001595229800001 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Sage Publications Ltd | |
| dc.relation.ispartof | Science Progress | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20260623 | |
| dc.subject | A Beta 1-42 | |
| dc.subject | Alzheimer'S Disease | |
| dc.subject | Boron Compounds | |
| dc.subject | Neuroprotective | |
| dc.subject | Oxidative Effect | |
| dc.title | Synthesized boron compounds: Neurotoxic and oxidative effects in an in vitro model of Alzheimer's disease | |
| dc.type | Article |












